Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Sin Wook Kim, Wan Cheol Lee, Ma Tae Kim, Kyungtae Ko, Won Ki Lee, Choong Hyun Lee, Je-Jong Kim, Dae Yul Yang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The aim of the present study was to evaluate the effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia. Materials and Methods: A total of 138 male LUTS patients aged more than 50 years with an International Prostate Symptom Score (IPSS) ≥8 were enrolled in this open-la-bel, multicenter, prospective, noncomparative observational study. Clinical assess-ments included IPSS, quality of life (QoL) index, International Index of Erectile Function (IIEF), Danish Prostate Symptom Score (DAN-PSS), and an early morning erection questionnaire. The data were recorded at baseline and at 1 and 3 months after treatment with tamsulosin 0.2 mg/d. Adverse events were analyzed in all patients. Results: During the study period of 3 months, the IPSS and QoL index significantly improved from baseline by -11.40±9.40 and -1.11±1.36, respectively (p<0.001). However, there were no clinically relevant changes in total IIEF score (mean difference, 1.63±15.50; p=0.406) or the 5 subdomains (p>0.05). Furthermore, DAN-PSS weighted scores (A×B) showed no clinically relevant changes (mean difference on Q1, Q2, and Q3: -0.45±2.94, 0.27±2.50, and -1.27±2.27, p>0.05). In addition, there were no clin-ically significant changes in responses on the early morning erection questionnaire. Conclusions: Tamsulosin at the dose of 0.2 mg significantly improved the IPSS and the QoL index compared with baseline. However, tamsulosin did not exhibit any significant impact on sexual function or any negative impact on ejaculatory function.

Original languageEnglish
Pages (from-to)697-702
Number of pages6
JournalKorean Journal of Urology
Volume54
Issue number10
DOIs
Publication statusPublished - 2013 Oct 1

Fingerprint

tamsulosin
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Prostate
Quality of Life
Observational Studies

Keywords

  • Ejaculation
  • Erectile dysfunction
  • Lower urinary tract symptoms
  • Prostatic hyperplasia
  • Tamsulosin

ASJC Scopus subject areas

  • Urology

Cite this

Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. / Kim, Sin Wook; Lee, Wan Cheol; Kim, Ma Tae; Ko, Kyungtae; Lee, Won Ki; Lee, Choong Hyun; Kim, Je-Jong; Yang, Dae Yul.

In: Korean Journal of Urology, Vol. 54, No. 10, 01.10.2013, p. 697-702.

Research output: Contribution to journalArticle

Kim, Sin Wook ; Lee, Wan Cheol ; Kim, Ma Tae ; Ko, Kyungtae ; Lee, Won Ki ; Lee, Choong Hyun ; Kim, Je-Jong ; Yang, Dae Yul. / Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. In: Korean Journal of Urology. 2013 ; Vol. 54, No. 10. pp. 697-702.
@article{a815a748436841e19c9bf07cbd6973ed,
title = "Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia",
abstract = "Purpose: The aim of the present study was to evaluate the effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia. Materials and Methods: A total of 138 male LUTS patients aged more than 50 years with an International Prostate Symptom Score (IPSS) ≥8 were enrolled in this open-la-bel, multicenter, prospective, noncomparative observational study. Clinical assess-ments included IPSS, quality of life (QoL) index, International Index of Erectile Function (IIEF), Danish Prostate Symptom Score (DAN-PSS), and an early morning erection questionnaire. The data were recorded at baseline and at 1 and 3 months after treatment with tamsulosin 0.2 mg/d. Adverse events were analyzed in all patients. Results: During the study period of 3 months, the IPSS and QoL index significantly improved from baseline by -11.40±9.40 and -1.11±1.36, respectively (p<0.001). However, there were no clinically relevant changes in total IIEF score (mean difference, 1.63±15.50; p=0.406) or the 5 subdomains (p>0.05). Furthermore, DAN-PSS weighted scores (A×B) showed no clinically relevant changes (mean difference on Q1, Q2, and Q3: -0.45±2.94, 0.27±2.50, and -1.27±2.27, p>0.05). In addition, there were no clin-ically significant changes in responses on the early morning erection questionnaire. Conclusions: Tamsulosin at the dose of 0.2 mg significantly improved the IPSS and the QoL index compared with baseline. However, tamsulosin did not exhibit any significant impact on sexual function or any negative impact on ejaculatory function.",
keywords = "Ejaculation, Erectile dysfunction, Lower urinary tract symptoms, Prostatic hyperplasia, Tamsulosin",
author = "Kim, {Sin Wook} and Lee, {Wan Cheol} and Kim, {Ma Tae} and Kyungtae Ko and Lee, {Won Ki} and Lee, {Choong Hyun} and Je-Jong Kim and Yang, {Dae Yul}",
year = "2013",
month = "10",
day = "1",
doi = "10.4111/kju.2013.54.10.697",
language = "English",
volume = "54",
pages = "697--702",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "10",

}

TY - JOUR

T1 - Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

AU - Kim, Sin Wook

AU - Lee, Wan Cheol

AU - Kim, Ma Tae

AU - Ko, Kyungtae

AU - Lee, Won Ki

AU - Lee, Choong Hyun

AU - Kim, Je-Jong

AU - Yang, Dae Yul

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Purpose: The aim of the present study was to evaluate the effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia. Materials and Methods: A total of 138 male LUTS patients aged more than 50 years with an International Prostate Symptom Score (IPSS) ≥8 were enrolled in this open-la-bel, multicenter, prospective, noncomparative observational study. Clinical assess-ments included IPSS, quality of life (QoL) index, International Index of Erectile Function (IIEF), Danish Prostate Symptom Score (DAN-PSS), and an early morning erection questionnaire. The data were recorded at baseline and at 1 and 3 months after treatment with tamsulosin 0.2 mg/d. Adverse events were analyzed in all patients. Results: During the study period of 3 months, the IPSS and QoL index significantly improved from baseline by -11.40±9.40 and -1.11±1.36, respectively (p<0.001). However, there were no clinically relevant changes in total IIEF score (mean difference, 1.63±15.50; p=0.406) or the 5 subdomains (p>0.05). Furthermore, DAN-PSS weighted scores (A×B) showed no clinically relevant changes (mean difference on Q1, Q2, and Q3: -0.45±2.94, 0.27±2.50, and -1.27±2.27, p>0.05). In addition, there were no clin-ically significant changes in responses on the early morning erection questionnaire. Conclusions: Tamsulosin at the dose of 0.2 mg significantly improved the IPSS and the QoL index compared with baseline. However, tamsulosin did not exhibit any significant impact on sexual function or any negative impact on ejaculatory function.

AB - Purpose: The aim of the present study was to evaluate the effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia. Materials and Methods: A total of 138 male LUTS patients aged more than 50 years with an International Prostate Symptom Score (IPSS) ≥8 were enrolled in this open-la-bel, multicenter, prospective, noncomparative observational study. Clinical assess-ments included IPSS, quality of life (QoL) index, International Index of Erectile Function (IIEF), Danish Prostate Symptom Score (DAN-PSS), and an early morning erection questionnaire. The data were recorded at baseline and at 1 and 3 months after treatment with tamsulosin 0.2 mg/d. Adverse events were analyzed in all patients. Results: During the study period of 3 months, the IPSS and QoL index significantly improved from baseline by -11.40±9.40 and -1.11±1.36, respectively (p<0.001). However, there were no clinically relevant changes in total IIEF score (mean difference, 1.63±15.50; p=0.406) or the 5 subdomains (p>0.05). Furthermore, DAN-PSS weighted scores (A×B) showed no clinically relevant changes (mean difference on Q1, Q2, and Q3: -0.45±2.94, 0.27±2.50, and -1.27±2.27, p>0.05). In addition, there were no clin-ically significant changes in responses on the early morning erection questionnaire. Conclusions: Tamsulosin at the dose of 0.2 mg significantly improved the IPSS and the QoL index compared with baseline. However, tamsulosin did not exhibit any significant impact on sexual function or any negative impact on ejaculatory function.

KW - Ejaculation

KW - Erectile dysfunction

KW - Lower urinary tract symptoms

KW - Prostatic hyperplasia

KW - Tamsulosin

UR - http://www.scopus.com/inward/record.url?scp=84886283152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886283152&partnerID=8YFLogxK

U2 - 10.4111/kju.2013.54.10.697

DO - 10.4111/kju.2013.54.10.697

M3 - Article

C2 - 24175045

AN - SCOPUS:84886283152

VL - 54

SP - 697

EP - 702

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 10

ER -